Handa Pharmaceuticals reported a stellar 2025, driven by the successful market penetration of its 505(b)(2) high-barrier specialty drugs and the out-licensing of its leukemia medication, Phyrago.

• Financial Breakdown: Annual revenue soared 108% to NT$1.729 billion, while operating profit jumped 123% to NT$934 million. This resulted in an EPS of $4.85, nearly double the previous year's performance.
• 2026 Growth Catalysts: Handa is seeing rapid adoption of Phyrago in the U.S. market. Additionally, the company has submitted an NDA for its multi-target oncology drug, HND-039, and is actively preparing for a U.S. launch. The board has proposed a cash dividend of NT$2 per share.

Resource: 漢達去年獲利翻倍跳，EPS 4.85元創歷史新高，擬配息2元